226 related articles for article (PubMed ID: 25512816)
1. Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia.
Cyrus A; Kabir A; Goodarzi D; Talaei A; Moradi A; Rafiee M; Moghimi M; Shahbazi E; Farmani E
Korean J Urol; 2014 Dec; 55(12):814-20. PubMed ID: 25512816
[TBL] [Abstract][Full Text] [Related]
2. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
Liu Q; Zhu Y; Liu J; Qi J; Kang J
Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
[TBL] [Abstract][Full Text] [Related]
5. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
Zhao S; Tang J; Shao S; Yan Y
Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.
Gacci M; Vignozzi L; Sebastianelli A; Salvi M; Giannessi C; De Nunzio C; Tubaro A; Corona G; Rastrelli G; Santi R; Nesi G; Serni S; Carini M; Maggi M
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):101-6. PubMed ID: 23165431
[TBL] [Abstract][Full Text] [Related]
7. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
[TBL] [Abstract][Full Text] [Related]
8. The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study.
Fu Y; Zhou Z; Yang B; Zhang K; He L; Zhang X
Urol Int; 2016; 97(3):330-335. PubMed ID: 27509202
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
10. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms.
Kwon H; Kang HC; Lee JH
Urology; 2013 Jun; 81(6):1325-9. PubMed ID: 23602796
[TBL] [Abstract][Full Text] [Related]
11. Periprostatic fat thickness measured on MRI correlates with lower urinary tract symptoms, erectile function, and benign prostatic hyperplasia progression.
Zhang B; Chen X; Liu YH; Gan Y; Liu PH; Chen Z; Xia WP; Dai GY; Ru F; Jiang ZX; He Y
Asian J Androl; 2021; 23(1):80-84. PubMed ID: 32859870
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms.
De Nunzio C; Cindolo L; Gacci M; Pellegrini F; Carini M; Lombardo R; Franco G; Tubaro A
Urology; 2014 Nov; 84(5):1181-7. PubMed ID: 25443931
[TBL] [Abstract][Full Text] [Related]
13. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
[TBL] [Abstract][Full Text] [Related]
14. Association of lower urinary tract symptom/benign prostatic hyperplasia measures with international index of erectile function 5 in middle-aged policemen of Korea and the role of metabolic syndrome and testosterone in their relationship.
Lee JH; Kwon H; Park YW
Urology; 2013 Nov; 82(5):1008-12. PubMed ID: 24041675
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
Ghadian A; Rezaei M
Inflammopharmacology; 2017 Aug; 25(4):451-458. PubMed ID: 28391389
[TBL] [Abstract][Full Text] [Related]
16. Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients.
Russo GI; Vanella L; Castelli T; Cimino S; Reale G; Urzì D; Li Volti G; Gacci M; Carini M; Motta F; Caltabiano R; Puzzo L; Sorrenti V; Morgia G
World J Urol; 2016 Aug; 34(8):1183-92. PubMed ID: 26621207
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
18. Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
Bulut S; Ozden C; Aktas BK; Deren T; Tagci S; Gokkaya CS; Baykam MM; Memis A
Urol Int; 2015; 94(2):181-6. PubMed ID: 25139617
[TBL] [Abstract][Full Text] [Related]
19. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
